What is ATN (Acute Tubular Necrosis)?
ATN is a form of intrinsic acute kidney injury characterized by damage to the renal tubular epithelial cells, typically resulting from ischemic or nephrotoxic insults, and represents the most common type of structural kidney damage in hospitalized patients with AKI. 1, 2
Pathophysiology and Mechanism
ATN develops when renal tubular cells undergo injury and death following:
- Ischemic insults: Prolonged renal hypoperfusion leading to cellular hypoxia
- Nephrotoxic exposures: Aminoglycosides, contrast agents, NSAIDs, calcineurin inhibitors (cyclosporine, tacrolimus) 3, 4
- Sepsis-related injury: Renal hypoperfusion combined with inflammatory mediators 5
The pathophysiology involves renal hypoperfusion and ischemia as central mechanisms, though the actual histopathologic findings are often subtle and inconstant despite profound kidney dysfunction 6. Importantly, ATN represents a syndrome of physiologic and pathologic dissociation—meaning severe functional impairment can occur with minimal visible tubular necrosis on biopsy 6.
Clinical Context and Timing
ATN occurs most commonly in specific clinical scenarios:
- Post-transplant setting: ATN is the most frequent cause of delayed graft function in the immediate postoperative period (<1 week), particularly with cadaveric grafts 7, 4
- Cirrhosis patients: ATN accounts for the intrinsic/structural component of AKI, distinct from hepatorenal syndrome (HRS-AKI) 1, 2
- Septic patients: Combination of acute renal failure and sepsis carries 70% mortality 5
- ICU patients: Represents the predominant form of hospital-acquired AKI 8
Diagnostic Approach
The diagnosis of ATN requires distinguishing it from prerenal azotemia and other causes of AKI through a combination of clinical context, urinary findings, and biomarkers 2, 9:
Urinary Findings
- Fractional excretion of sodium (FENa) >1% suggests ATN rather than prerenal causes (FENa <1%) 2
- Muddy brown casts and renal tubular epithelial cells on urine sediment are characteristic 2
- Urinary sodium typically >20 mEq/L (versus <10 mEq/L in prerenal states)
Biomarkers for Differential Diagnosis
Urinary NGAL (neutrophil gelatinase-associated lipocalin) can distinguish ATN from HRS-AKI in cirrhosis patients, with elevated levels indicating tubular damage 1, 10. Other damage biomarkers include interleukin-18 and kidney injury molecule-1 9.
Key Distinction from Prerenal AKI
Unlike prerenal azotemia, ATN does not respond to volume expansion with albumin (1 g/kg up to 100g) with return of serum creatinine to within 0.3 mg/dL of baseline 2. This lack of response to fluid challenge is a critical diagnostic feature.
Clinical Implications and Prognosis
ATN carries significant mortality risk, with rates of 50-80% in hospitalized patients, largely driven by associated sepsis (30-70% of deaths) and multiorgan failure 8. Even transient episodes negatively impact mid-term survival 1.
Management Principles
There is no specific therapy to reverse established ATN—management focuses on:
- Immediate discontinuation of nephrotoxic agents (NSAIDs, aminoglycosides, calcineurin inhibitors) 3, 2
- Avoidance of further insults: Remove IV lines, bladder catheters when possible to prevent sepsis 8
- Supportive renal replacement therapy when indicated for volume overload, uremia, or electrolyte disturbances 5
- Aggressive infection surveillance and treatment given sepsis drives mortality 8
Recovery Considerations
ATN can progress to chronic kidney disease if diagnosis is delayed or exposure to the culprit agent continues 11. The presence of tubular damage markers indicates structural injury that may not fully recover, unlike pure functional AKI 9.
Critical Pitfalls
- Do not assume bland urine sediment excludes ATN—early ATN may not yet show cellular casts 2
- Do not rely solely on FENa in patients recently on diuretics—this invalidates the interpretation 2
- Do not delay nephrology consultation—early involvement improves survival 8
- In cirrhosis, do not confuse ATN with HRS-AKI—they require different management approaches, with HRS-AKI responding to vasoconstrictors plus albumin while ATN does not 10, 2